Cepheid's Connie Savor, MD, MBA, explains where its 13-pathogen respiratory panel fits in diagnostic stewardship and antibiotic decisions.
|Articles|March 1, 1996
The American Journal of Managed Care
- March 1996
- Volume 2
- Issue 3
Managed Care Cost Containment and the Law of Unintended Consequences
Advertisement
Articles in this issue
over 30 years ago
Cost-Effectiveness of Chiropractic Care in a Managed Care Settingover 30 years ago
The Costs of Allergic Rhinitisover 30 years ago
PACE: Managed Care for the Frail Elderlyover 30 years ago
Ideas and Initiatives in the Managed Care Marketplaceover 30 years ago
The Impact of Managed Care on Community PsychiatryAdvertisement
Related to this article
Older adults on Medicare report the best access to care among 10 countries but more cost-related problems and higher out-of-pocket spending.
Two inSPire2026 posters detail how health system specialty pharmacy teams support patients with ATTR-CM.
Patients with Sjögren disease diagnosed over a year after symptom onset had 2.3 times the odds of moderate or greater disease activity, a US survey found.
An estimated 44,052 sports eye injuries were treated in 2025 and 1262 pickleball eye injuries in 2024; 99% of lawnmower eye injuries were at home.
Pola-R-GemOx extends median overall survival to 19.5 months in transplant-ineligible R/R DLBCL, per POLARGO.
Teva's Weltruza, a once-monthly subcutaneous olanzapine injection, requires no loading doses, oral supplementation, or postinjection monitoring.
Even when physicians prescribe guideline-preferred therapies, step therapy and prior authorization can delay or restrict access to CLL therapies.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves IV, Subcutaneous Atezolizumab for dMMR Colon Cancer
2
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
3
Bumetanide Nasal Spray Targets Heart Failure Edema Before IV
4
Timing COVID-19 Protection With VYD2311: Michael Mina, MD, PhD
5